Gewinn- und Verlustrechnung von Hims & Hers Health, Inc.

New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.

RADNOR, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options

Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.

New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.

Hims & Hers Health Inc. (NYSE:HIMS) CEO Andrew Dudum defended the telehealth company as it navigates a U.S. Federal Trade Commission lawsuit concerning data privacy and advertising practices.

Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation. International revenue surged over 17-fold YoY to $131M, with Eucalyptus acquisition and new markets fueling growth and future $600M+ 2026 target. AI investment aims to reduce customer-support costs and improve retention, with payback expected in 12–18 months as in-house capabilities scale.

Philadelphia, Pennsylvania--(Newsfile Corp. - August 19, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.

The disposition involved 6,490 shares worth about $183,000 at a price of $28.15 per share on August 14. All shares were withheld by the issuer to cover tax obligations following the quarterly vesting of restricted stock units (RSUs).

The disposition involved 21,500 shares valued at about $605,000 as of the August 14 transaction date. Soleil Boughton maintains direct ownership of 339,000 shares and holds additional derivative securities following the liquidation.